Mizuho analyst Salim Syed lowered the firm’s price target on Nkarta (NKTX) to $12 from $14 and keeps an Outperform rating on the shares. The firm updated models in the small-cap biotech space following the Q4 reports.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX:
- Buy Rating Initiated on NKX019’s Differentiated CAR‑NK Platform and De‑Risked Autoimmune Opportunity Ahead of 2026 Proof‑of‑Concept Data
- Nkarta price target raised to $11 from $10 at Needham
- Nkarta Launches $100 Million At-the-Market Stock Offering
- Nkarta files $350M mixed securities shelf
- Nkarta reports Q4 EPS (37c), consensus (29c)